SCHEMBL4619006

SCHEMBL4619006

Cc1ccc(O)c(C(C(=O)O)c2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.54
MEN1 O00255 3/20 0.54
HTT P42858 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
GAA P10253 2/20 0.52
HPGD P15428 1/20 0.52
CHRM2 P08172 2/20 0.52
CHRM5 P08912 2/20 0.52
CHRM1 P11229 2/20 0.52
CHRM3 P20309 2/20 0.52
HRH1 P35367 2/20 0.52
ADRB2 P07550 1/20 0.52
CX3CR1 P49238 1/20 0.52
TMEM97 Q5BJF2 1/20 0.52
FFAR4 Q5NUL3 1/20 0.52
SIGMAR1 Q99720 1/20 0.52
MAPT P10636 2/20 0.50
PTGS1 P23219 2/20 0.50
LMNA P02545 1/20 0.50
ESR1 P03372 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27965897 0.84 KMT2A (0.52) KMT2AMEN1HTTNPSR1GAA
SCHEMBL4640916 0.82 KMT2A (0.49) KMT2AMEN1HTTNPSR1GAA
SCHEMBL9447445 0.81 CNR1 (0.48) KMT2AMEN1HTTNPSR1GAA
SCHEMBL14677603 0.81 KMT2A (0.48) KMT2AMEN1HTTNPSR1CACNA1C
SCHEMBL51095 0.79 CHRM1 (0.55) KMT2AMEN1HTTNPSR1GAA
SCHEMBL28499022 0.79 CHRM1 (0.55) KMT2AMEN1HTTNPSR1GAA
SCHEMBL11363822 0.78 MEN1 (0.50) KMT2AMEN1GAAHPGDLMNA
SCHEMBL3997027 0.78 KMT2A (0.67) KMT2AMEN1HTTNPSR1GAA
SCHEMBL222362 0.77 CHRM1 (0.57) KMT2AMEN1HTTNPSR1GAA
SCHEMBL29509825 0.77 CHRM1 (0.57) KMT2AMEN1HTTNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US disclosed
EP-1888525-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-02-20 EP disclosed
WO-2006117754-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 KMT2A 3710/4885MEN1 1514/4885HTT 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.